HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

CYC065

inhibits both CDK12 and CDK13; structure in first source

Networked: 7 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- Fused-Ring Heterocyclic Compounds
  - 2-Ring Heterocyclic Compounds
    - Purines: 651
      - Purine Nucleosides: 360
        Adenosine: 12431
        CYC065: 7
Nucleic Acids, Nucleotides, and Nucleosides: 1
- Nucleosides: 6847
  - Purine Nucleosides: 360
    - Adenosine: 12431
      - CYC065: 7
  - Ribonucleosides: 49
    - Adenosine: 12431
      - CYC065: 7

Experts

1.	Zheleva, Daniella: 3 articles (01/2022 - 01/2020)
2.	Blake, David: 2 articles (01/2022 - 01/2020)
3.	Clarke, Paul A: 2 articles (11/2020 - 01/2020)
4.	Workman, Paul: 2 articles (11/2020 - 01/2020)
5.	Chen, Rong: 1 article (01/2022)
6.	Chen, Yuling: 1 article (01/2022)
7.	Keating, Michael J: 1 article (01/2022)
8.	Plunkett, William: 1 article (01/2022)
9.	Wierda, William G: 1 article (01/2022)
10.	Xiong, Ping: 1 article (01/2022)

Related Diseases

1.	Neoplasms (Cancer) 01/01/2021 - "Correction: Fadraciclib (CYC065), a novel CDK inhibitor, targets key pro-survival and oncogenic pathways in cancer." 01/01/2020 - "Fadraciclib (CYC065), a novel CDK inhibitor, targets key pro-survival and oncogenic pathways in cancer." 12/31/2023 - "CDK2/9 antagonism with CYC065 (Fadraciclib)-treatment disordered centrosome stoichiometry in aneuploid cancer cells, preventing centrosome clustering. " 01/01/2021 - "Thus, induced anaphase catastrophe after CYC065 treatment can combat aneuploid cancers despite KRAS oncoprotein expression. " 01/01/2021 - "A Novel CDK2/9 Inhibitor CYC065 Causes Anaphase Catastrophe and Represses Proliferation, Tumorigenesis, and Metastasis in Aneuploid Cancers."
2.	Aneuploidy (Aneuploid) 12/31/2023 - "CDK2/9 antagonism with CYC065 (Fadraciclib)-treatment disordered centrosome stoichiometry in aneuploid cancer cells, preventing centrosome clustering. " 01/01/2021 - "Thus, induced anaphase catastrophe after CYC065 treatment can combat aneuploid cancers despite KRAS oncoprotein expression. " 01/01/2021 - "A Novel CDK2/9 Inhibitor CYC065 Causes Anaphase Catastrophe and Represses Proliferation, Tumorigenesis, and Metastasis in Aneuploid Cancers." 01/01/2021 - "To establish induced anaphase catastrophe as a clinically tractable antineoplastic mechanism, induced anaphase catastrophe was explored in different aneuploid cancers after treatment with CYC065 (Cyclacel), a CDK2/9 inhibitor. "
3.	Carcinogenesis 01/01/2021 - "A Novel CDK2/9 Inhibitor CYC065 Causes Anaphase Catastrophe and Represses Proliferation, Tumorigenesis, and Metastasis in Aneuploid Cancers."
4.	B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia) 01/01/2022 - "Cyclin-dependent kinase inhibitor fadraciclib (CYC065) depletes anti-apoptotic protein and synergizes with venetoclax in primary chronic lymphocytic leukemia cells."
5.	Pancreatic Neoplasms (Pancreatic Cancer) 01/01/2021 - "CYC065 treatment augmented anaphase catastrophe in diverse cancers including lymphoma, lung, colon, and pancreatic cancers, despite KRAS oncoprotein expression. "

Related Drugs and Biologics

1.	Focal Adhesion Protein-Tyrosine Kinases
2.	Apoptosis Regulatory Proteins
3.	Cyclin-Dependent Kinases (cdk Proteins)
4.	Adrenergic Agents (Adrenergic Drugs)
5.	Oncogene Proteins (Oncogene Protein)
6.	Proteins (Proteins, Gene)
7.	Antineoplastic Agents (Antineoplastics)
8.	Temozolomide (Temodar)
9.	venetoclax

Related Therapies and Procedures

1.	Therapeutics
2.	Aftercare (After-Treatment)